Óskar Ö. Hálfdánarson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Óskar Ö. Hálfdánarson has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Helga Zoega
Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
4 shared publications Helga M. Ogmundsdottir
Faculty of Medicine, Cancer Research Laboratory, BioMedical Center, University of Iceland, Reykjavik, Iceland
3 shared publicationsMargret H. Ogmundsdottir
Department of Biochemistry and Molecular Biology, Faculty of Medicine, BioMedical Center, University of Iceland, Reykjavík, Iceland
3 shared publications- Anton Pottegård
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
2 shared publications - Helle Kieler
Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Sigrun Helga Lund
Faculty of Physical Sciences, University of Iceland
2 shared publications
Latest Publications
- Open Access
- 22 November 2021
- Published by BMJ in Evidence Based Mental Health
- Vol. 25 (2) , 54-62
Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study
Background: Antipsychotics are increasingly used among women of childbearing age and during pregnancy. Objective: To determine whether children exposed to antipsychotics in utero are at increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), accounting for maternal diagnoses of bipolar, psychotic and other psychiatric disorders. Design Population-based cohort study, including a sibling analysis. Setting Nationwide data on all pregnant women and their live-born singletons in Denmark (1997-2017), Finland (1996-2016), Iceland (2004-2017), Norway (2004-2017), and Sweden (2006-2016). Participants 4 324 086 children were eligible for inclusion to the study cohort. Intervention Antipsychotic exposure in utero, assessed by pregnancy trimester, type of antipsychotic, and varying patterns of use. Main outcome measures Non-mutually exclusive diagnoses of ADHD and ASD. We used Cox proportional hazard models to calculate hazard ratios (HRs) controlling for maternal psychiatric disorders and other potential confounding factors. Findings: Among 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics in utero. During a median follow-up of 10 years, we identified 72 257 children with ADHD and 38 674 children with ASD. Unadjusted HRs were raised for both outcomes but shifted substantially towards the null after adjustment; 1.10 (95%CI 1.00 to 1.27) for ADHD and 1.12 (0.97 to 1.29) for ASD. Adjusted HRs remained consistent by trimester of exposure and type of antipsychotic. Comparing in utero exposure with pre-pregnancy use yielded HRs of 0.74 (0.62 to 0.87) for ADHD and 0.88 (0.70 to 1.10) for ASD. Sibling analyses yielded HRs of 1.14 (0.79 to 1.64) for ADHD and 1.34 (0.75 to 2.39) for ASD. Discussion: Our findings suggest little or no increased risk of child ADHD or ASD after in utero exposure to antipsychotics. Clinical implications: Results regarding child neurodevelopment are reassuring for women who need antipsychotics during pregnancy.
- 22 November 2021
- Published by BMJ in Evidence Based Mental Health
- Vol. 25 (2) , 54-62
Open AccessAntipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study
Background: Antipsychotics are increasingly used among women of childbearing age and during pregnancy. Objective: To determine whether children exposed to antipsychotics in utero are at increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), accounting for maternal diagnoses of bipolar, psychotic and other psychiatric disorders. Design Population-based cohort study, including a sibling analysis. Setting Nationwide data on all pregnant women and their live-born singletons in Denmark (1997-2017), Finland (1996-2016), Iceland (2004-2017), Norway (2004-2017), and Sweden (2006-2016). Participants 4 324 086 children were eligible for inclusion to the study cohort. Intervention Antipsychotic exposure in utero, assessed by pregnancy trimester, type of antipsychotic, and varying patterns of use. Main outcome measures Non-mutually exclusive diagnoses of ADHD and ASD. We used Cox proportional hazard models to calculate hazard ratios (HRs) controlling for maternal psychiatric disorders and other potential confounding factors. Findings: Among 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics in utero. During a median follow-up of 10 years, we identified 72 257 children with ADHD and 38 674 children with ASD. Unadjusted HRs were raised for both outcomes but shifted substantially towards the null after adjustment; 1.10 (95%CI 1.00 to 1.27) for ADHD and 1.12 (0.97 to 1.29) for ASD. Adjusted HRs remained consistent by trimester of exposure and type of antipsychotic. Comparing in utero exposure with pre-pregnancy use yielded HRs of 0.74 (0.62 to 0.87) for ADHD and 0.88 (0.70 to 1.10) for ASD. Sibling analyses yielded HRs of 1.14 (0.79 to 1.64) for ADHD and 1.34 (0.75 to 2.39) for ASD. Discussion: Our findings suggest little or no increased risk of child ADHD or ASD after in utero exposure to antipsychotics. Clinical implications: Results regarding child neurodevelopment are reassuring for women who need antipsychotics during pregnancy.
- 23 December 2019
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 126 (6) , 484-491
Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer
Proton pump inhibitors (PPIs) are commonly used drugs among cancer patients. Due to conflicting reports on their safety, we aimed to determine whether PPI use is associated with mortality among prostate cancer patients. In this population‐based cohort study, we identified incident diagnoses of prostate cancer between 2007 and 2012 (n = 1058). Follow‐up was from 12 months after diagnosis until death, emigration or end the of study. Post‐diagnosis use was defined as ≥2 filled prescriptions following diagnosis. We used time‐dependent Cox proportional hazard regression models to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer‐specific and all‐cause mortality associated with post‐diagnosis use of PPIs. We identified 347 (32.8%) post‐diagnosis PPI users and 711 (67.2%) non‐users after diagnosis. Of the 347 patients using PPIs after diagnosis, 59 (17.0%) died due to any cause and 22 (6.3%) due to prostate cancer, compared with 144 (20.3%) and 76 (10.7%) among non‐users after diagnosis, respectively. Post‐diagnosis PPI use was not associated with prostate cancer‐specific mortality (HR 0.88; 95% CI: 0.52‐1.48) or all‐cause mortality (HR 1.02; 95% CI: 0.73‐1.43). Contrary to a previous report, this study did not find evidence of an association between post‐diagnosis PPI use and mortality among prostate cancer patients.
- 23 December 2019
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 126 (6) , 484-491
Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer
Proton pump inhibitors (PPIs) are commonly used drugs among cancer patients. Due to conflicting reports on their safety, we aimed to determine whether PPI use is associated with mortality among prostate cancer patients. In this population‐based cohort study, we identified incident diagnoses of prostate cancer between 2007 and 2012 (n = 1058). Follow‐up was from 12 months after diagnosis until death, emigration or end the of study. Post‐diagnosis use was defined as ≥2 filled prescriptions following diagnosis. We used time‐dependent Cox proportional hazard regression models to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer‐specific and all‐cause mortality associated with post‐diagnosis use of PPIs. We identified 347 (32.8%) post‐diagnosis PPI users and 711 (67.2%) non‐users after diagnosis. Of the 347 patients using PPIs after diagnosis, 59 (17.0%) died due to any cause and 22 (6.3%) due to prostate cancer, compared with 144 (20.3%) and 76 (10.7%) among non‐users after diagnosis, respectively. Post‐diagnosis PPI use was not associated with prostate cancer‐specific mortality (HR 0.88; 95% CI: 0.52‐1.48) or all‐cause mortality (HR 1.02; 95% CI: 0.73‐1.43). Contrary to a previous report, this study did not find evidence of an association between post‐diagnosis PPI use and mortality among prostate cancer patients.
- 19 December 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (4) , 471-478
Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study
Purpose: Increased expression of Vacuolar‐type H+ ATPases (V‐ATPases), in the plasma membrane of cancer cells has been suggested to contribute to the development of aggressive cancer phenotypes by promoting acidic tumor microenvironments. Accumulating data suggest that proton pump inhibitors (PPIs) may elicit a chemopreventive effect via V‐ATPase inhibition in some cancers, but evidence is still limited. Therefore, we aimed to explore a potential preventive role of PPIs in this study.Methods: In this population‐based case‐control study, we identified incident cases of breast cancer (n = 1739), prostate cancer (n = 1897), and malignant melanoma (n = 385) in Iceland between 2005 and 2014 from the Icelandic Cancer Registry. We assessed varying levels of PPI use through record linkages to the Icelandic Medicines Registry. For each case, we selected up to 10 age‐matched, sex‐matched, and calendar‐matched population controls using risk‐set sampling. Using conditional logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) controlling for NSAID use.Results: Adjusted ORs associated with ever use of PPIs were 1.03 (95% CI: 0.92‐1.16) for breast cancer, 1.12 (95% CI: 1.00‐1.25) for prostate cancer, and 0.84 (95% CI: 0.69‐1.12) for malignant melanoma. Analyses of high use of PPIs (≥1000 DDDs) yielded ORs of 0.97 (95% CI: 0.78‐1.19), 1.20 (0.99‐1.47), and 0.59 (0.40‐1.13) for breast cancer, prostate cancer, and malignant melanoma, respectively. Analyses of cumulative exposure to PPIs did not support a dose‐response relationship for any of the three cancer types.Conclusions: Our findings do not support a chemopreventive effect of PPI use on breast cancer, prostate cancer, or malignant melanoma.
- 19 December 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (4) , 471-478
Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study
Purpose: Increased expression of Vacuolar‐type H+ ATPases (V‐ATPases), in the plasma membrane of cancer cells has been suggested to contribute to the development of aggressive cancer phenotypes by promoting acidic tumor microenvironments. Accumulating data suggest that proton pump inhibitors (PPIs) may elicit a chemopreventive effect via V‐ATPase inhibition in some cancers, but evidence is still limited. Therefore, we aimed to explore a potential preventive role of PPIs in this study.Methods: In this population‐based case‐control study, we identified incident cases of breast cancer (n = 1739), prostate cancer (n = 1897), and malignant melanoma (n = 385) in Iceland between 2005 and 2014 from the Icelandic Cancer Registry. We assessed varying levels of PPI use through record linkages to the Icelandic Medicines Registry. For each case, we selected up to 10 age‐matched, sex‐matched, and calendar‐matched population controls using risk‐set sampling. Using conditional logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) controlling for NSAID use.Results: Adjusted ORs associated with ever use of PPIs were 1.03 (95% CI: 0.92‐1.16) for breast cancer, 1.12 (95% CI: 1.00‐1.25) for prostate cancer, and 0.84 (95% CI: 0.69‐1.12) for malignant melanoma. Analyses of high use of PPIs (≥1000 DDDs) yielded ORs of 0.97 (95% CI: 0.78‐1.19), 1.20 (0.99‐1.47), and 0.59 (0.40‐1.13) for breast cancer, prostate cancer, and malignant melanoma, respectively. Analyses of cumulative exposure to PPIs did not support a dose‐response relationship for any of the three cancer types.Conclusions: Our findings do not support a chemopreventive effect of PPI use on breast cancer, prostate cancer, or malignant melanoma.
- Open Access
- 1 January 2018
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 11
Proton-pump inhibitors among adults: a nationwide drug-utilization study
The use of proton-pump inhibitors (PPIs) has grown worldwide, and there are concerns about increased unsubstantiated long-term use. The aim of the study was to describe the real-world use of PPIs over the past decade in an entire national population. This was a nationwide population-based drug-utilization study. Patterns of outpatient PPI use among adults in Iceland between 2003 and 2015 were investigated, including annual incidence and prevalence, duration of use, and dose of tablet used (lower versus higher), as well as the proportion of PPI use attributable to gastroprotection. We observed 1,372,790 prescription fills over the entire study period, of which 95% were for higher-dose PPIs. Annual incidence remained stable across time (3.3–4.1 per 100 persons per year), while the annual prevalence increased from 8.5 per 100 persons to 15.5 per 100 persons. Prevalence increased with patient age and was higher among women than men. Duration of treatment increased with patients’ age (36% of users over 80 years remained on treatment after 1 year compared with 13% of users aged 19–39 years), and was longer among those initiating on a higher dose compared with a lower dose. The proportion of PPI users concurrently using nonsteroidal anti-inflammatory drugs decreased over the study period, while the proportion concurrently using acetylsalicylic acid, oral anticoagulants, or platelet inhibitors increased. In this nationwide study, a considerable increase in overall outpatient use of PPIs over a 13-year period was observed, particularly among older adults. Patients were increasingly treated for longer durations than recommended by clinical guidelines and mainly with higher doses.
- 1 January 2018
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 11
Open AccessProton-pump inhibitors among adults: a nationwide drug-utilization study
The use of proton-pump inhibitors (PPIs) has grown worldwide, and there are concerns about increased unsubstantiated long-term use. The aim of the study was to describe the real-world use of PPIs over the past decade in an entire national population. This was a nationwide population-based drug-utilization study. Patterns of outpatient PPI use among adults in Iceland between 2003 and 2015 were investigated, including annual incidence and prevalence, duration of use, and dose of tablet used (lower versus higher), as well as the proportion of PPI use attributable to gastroprotection. We observed 1,372,790 prescription fills over the entire study period, of which 95% were for higher-dose PPIs. Annual incidence remained stable across time (3.3–4.1 per 100 persons per year), while the annual prevalence increased from 8.5 per 100 persons to 15.5 per 100 persons. Prevalence increased with patient age and was higher among women than men. Duration of treatment increased with patients’ age (36% of users over 80 years remained on treatment after 1 year compared with 13% of users aged 19–39 years), and was longer among those initiating on a higher dose compared with a lower dose. The proportion of PPI users concurrently using nonsteroidal anti-inflammatory drugs decreased over the study period, while the proportion concurrently using acetylsalicylic acid, oral anticoagulants, or platelet inhibitors increased. In this nationwide study, a considerable increase in overall outpatient use of PPIs over a 13-year period was observed, particularly among older adults. Patients were increasingly treated for longer durations than recommended by clinical guidelines and mainly with higher doses.
- 1 October 2017
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 27 (10) , 1064-1076
International trends in antipsychotic use: A study in 16 countries, 2005–2014
- 1 October 2017
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 27 (10) , 1064-1076
International trends in antipsychotic use: A study in 16 countries, 2005–2014